Leuject (Cladribine)

Cladribine is a pyrimidine nucleoside analog that is taken up by cells and phosphorylated to its active triphosphate form. This active metabolite incorporates into DNA, causing strand breaks and triggering programmed cell death, especially in rapidly dividing lymphocytes, thereby reducing abnormal immune activity.

The specific dose and schedule of Leuject are determined by the prescribing physician based on the patient’s diagnosis, disease severity, and individual health factors. Dosage decisions are made in accordance with approved clinical guidelines and local regulatory recommendations.

Cladribine’s safety in pregnancy and lactation has not been fully established. It is generally advised to avoid use in pregnant or breastfeeding women unless the potential benefits outweigh the risks, and to discuss alternative options with a healthcare professional.

To place an order, submit an enquiry on the Leuject product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with alternative therapies, cladribine offers a short‑course, targeted approach that can achieve durable remission in hairy cell leukemia and reduce relapse frequency in multiple sclerosis. Its dosing schedule is less frequent than many continuous immunosuppressants, but safety monitoring is essential due to immunosuppressive effects.

Leuject should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and follow any additional handling instructions provided by the supplier to maintain stability.

Leuject is given as a subcutaneous injection. The injection is performed by a qualified healthcare professional, following aseptic technique and the dosing schedule prescribed by the treating physician.

The most serious risks include severe infections due to profound lymphopenia, opportunistic infections, potential liver toxicity, and the rare possibility of secondary malignancies. Patients should be monitored closely for signs of infection, liver dysfunction, and abnormal blood counts throughout treatment.

Leuject is contraindicated in patients with active severe infections, those receiving live vaccines, and individuals with known hypersensitivity to cladribine or any excipients in the formulation. Caution is also advised for patients with significant renal or hepatic impairment.